Mary Woolley

Dear Research Advocate: The impact of the partial government shutdown – now entering its second month – continues to reverberate across the U.S., causing individual suffering and squandering progress at the expense of us all. Research!America signed on to two letters highlighting ways this shutdown is affecting the critical roles of FDA and NSF , not to mention the individuals impacted by their life-saving work. A picture (or graphic) is worth a thousand words: we have been using visuals via Twitter to make the case for ending the shutdown. I hope you’ll retweet and add your own voice to the conversation here . As we continue to push for a resolution to the shutdown, we must also work to...
Dear Research Advocate, The partial government shutdown continues, now at day 27. There are too many furloughed workers struggling to make ends meet, our nation’s parks and monuments are being ruined, research support by NSF has been put on hold, and drug approvals have slowed at FDA. For a run-down on the broadscale impact, see this USA Today article quoting ASBMB’s Ben Corb, and for a closer look at the toll the shutdown is taking on research, check out this article discussing the impact at the University of Wisconsin, emblematic of so many campuses nationwide. As a temporary patch, agency leaders have called back thousands of employees to work without pay. At the FDA, Commissioner Scott...
Dear Research Advocate: The government remains in a partial shutdown that began on December 22, taking a mounting toll on 800,000 federal workers, including those at FDA and NSF. The Alliance for a Stronger FDA has put together a “ Shutdown Toolkit ” detailing how this ongoing impasse is affecting us all. In a similar vein, the Coalition for National Science Funding has been sharing stories on social media that focus on how the shutdown is impacting NSF-funded research and programs, stifling discovery and sending a message of ‘no public confidence’ to aspiring young scientists. Clearly, the effects of the shutdown on research are multiple, disruptive and counterproductive. This New York...
Dear Research Advocate: In welcome news, last night the (departing) 115th Senate voted to confirm Dr. Kelvin Droegemeier as Director of the White House Office of Science and Technology Policy (OSTP). Research!America sent a thank you note acknowledging the roles Senate Commerce Committee leaders John Thune (R-SD) and Bill Nelson (D-FL) played in advancing the nomination. This confirmation is a great beginning for the new year – and the most recent evidence that advocacy works! Tomorrow marks Research!America’s 30th anniversary. There is no question that over three decades, the medical and health research advocacy community has become more organized and more effective. While our community...
Dear Research Advocate: The government is now in its sixth day of a partial shutdown that has left agencies including the Food and Drug Administration (FDA) and National Science Foundation (NSF) without the necessary resources to conduct their critical, multi-faceted work. Negotiations between the Congress and the White House reportedly remain at a stalemate. Last year, when the House and Senate voted to end a weeklong shutdown, Senate Majority Leader McConnell said he hoped everyone could remember that "brinksmanship and hostage-taking do not work. They make bipartisan progress harder – not easier – to achieve." Let’s face it: no one is heeding that lesson now. The path that will truly...
Dear Research Advocate: Votes and other Congressional activities were suspended this week to mourn the passing of our nation’s 41st President, George H.W. Bush. To prevent a government shutdown and provide more time to resolve disagreement around border wall funding, Congress agreed to another continuing resolution (CR) – now awaiting the President’s signature – to extend flat-funding for all remaining federal departments and agencies, including FDA and NSF, until December 21. This end-of-year CR scenario is all too familiar to advocates, and we must all stay the course to secure passage this year. Yesterday, Research!America and the Alliance for Aging Research sent a joint letter to...
Dear Research Advocate: This week has been rife with chilling public health news. You may have seen the widely-covered announcement that life expectancy in the United States has once again dropped, driven for a third year in a row by opioid (including fentanyl) abuse, a surge in suicide, especially in rural areas, and a spike in flu deaths. A sustained decline in life expectancy has not been seen in the U.S. for a century, since the devastation of World War I and the Pandemic flu of 1918. Read the full story . Also in the news are climate reports pointing to interconnected global health risks that are not going to go away on their own. Research and innovation are essential to ensuring our...
Dear Research Advocate: Earlier this week I had the privilege of meeting with and addressing faculty and students at Weill Cornell Graduate School of Medical Sciences and at Rutgers University. During both trips, it was truly energizing to witness the enthusiasm, and sense of accountability, more and more scientists (on every rung of the career ladder) have for influencing the direction of federal research funding and policy. I hope my presentations reinforced and bolstered those terrific instincts...at least that was the goal! As always, I learned easily as much as I shared, including being introduced to an innovative science communication course Rutgers has shaped for doctoral students...
Dear Research Advocate: At our post-election briefing this morning at AAAS in Washington, DC, the discussion focused on opportunities for advocacy given the composition and characteristics of the new Congress, and the importance of building new champions from among the nearly 100 new members of Congress. Of note — at last count, there are seven science-trained new members, a very welcome development! There is no doubt that a divided Congress can cause gridlock, but inaction is not a foregone conclusion, as was emphasized by our Chair, the Hon. Michael N. Castle. There are important, science-relevant issues, such as infrastructure, STEM education, and the opioid crisis, that both parties...
Dear Research Advocate: After Tuesday’s election, we may or may not know the exact composition of the 116th Congress, as there are likely to be some very, very close races. But there is little doubt that the picture will be clearer than it is now when it comes to the policy dynamics next year -- and that is what our post-election briefing on Thursday, November 8 from 10:00 to 11:30 a.m. EST at AAAS (1200 New York Ave, NW in Washington, DC) is all about. Register now! If history is any guide, the magnitude of change in Congress will affect the prospects for completing unfinished business during the lame-duck session of Congress; not surprisingly, the more turnover, the harder it is to build...

Pages

Sidebar Quote

You can change the image of things to come. But you can’t do it sitting on your hands … The science community should reach out to Congress and build bridges.
The Honorable John E. Porter